株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の嚢胞性線維症 (CF) 治療市場の分析と予測

Global Cystic Fibrosis Market Research Report - Forecast to 2022

発行 Market Research Future 商品コード 512182
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
世界の嚢胞性線維症 (CF) 治療市場の分析と予測 Global Cystic Fibrosis Market Research Report - Forecast to 2022
出版日: 2017年11月30日 ページ情報: 英文 60 Pages
概要

当レポートでは、世界の嚢胞性線維症 (CF) 治療市場について調査分析し、市場力学、収益実績・予測、主要企業プロファイル、競合情勢、経済要因などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 市場力学

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第4章 市場要因分析

  • ファイブフォースモデル

第5章 嚢胞性線維症 (CF) 治療市場:治療方法別

  • イントロダクション
  • 薬物治療
  • 装置
  • その他

第6章 嚢胞性線維症 (CF) 治療市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ

第7章 企業シェア分析

第8章 企業プロファイル

  • AbbVie
  • Allergan Plc
  • Chiesi Farmaceutici S.p.A.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences
  • Novartis AG 
  • Pharmaxis Ltd.
  • PTC Therapeutics
  • Vertex Pharmaceuticals Incorporated
目次

Introduction

The global cystic fibrosis market was valued at $ 3145.7 million in 2015 and expected to reach at $ 8852.2 million by 2022 at a CAGR of 13.5 % during the forecast period. The major factors responsible for the growth of global cystic fibrosis market are; development of new drugs and therapies, financial support from interest organizations in research and development of cystic fibrosis drugs and others. The growth barriers are high cost of the drugs and treatment among others.

The market is majorly categorized on the basis of treatment method types which is further segmented into medication, devices and other treatments and geographic regions. Globally, North America holds the largest market share of global cystic fibrosis market, registering 43.2 % in 2015.

The scope of Global Cystic fibrosis market study includes the market value, market size and a detailed analysis of vendor products and strategies.

Key Players

The leading players of the Global Cystic fibrosis market are AbbVie, Allergan Plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Vertex Pharmaceuticals Incorporated and others.

Study Objectives of Cystic Fibrosis Market Development and Demand Forecast to 2022 Market

Ø To provide insights about factors, influencing and affecting the market growth

Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries

Ø To provide historically and forecast revenue of the market segments based on type, and sub-segment for Global Cystic fibrosis market

Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market

Ø To provide economic factors that influence the Global Cystic fibrosis market

Target Audience

  • Cystic fibrosis companies
  • Hospitals & Clinics
  • Raw Material Suppliers
  • Key executive (CEO and COO) and strategy growth manager

Key Findings

  • On the basis of types, medication segment holds largest market share of global cystic fibrosis market, registering 76.4 % of total market in 2015.
  • US holds 66.48 % market share of North America cystic fibrosis Market and is expected to reach $ 2556.7 million by 2022 from $ 903.7million in 2015.

The reports also cover country level analysis:

  • North America
  • US
  • Canada
  • Europe
  • Western Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Republic of Korea
  • Rest of Asia-Pacific
  • Middle East & Africa

Table of Contents

Table of Contents:

1 Introduction

  • 1.1 Definition
  • 1.2 Scope of Study
  • 1.3 Research Objective
  • 1.4 Assumptions & Limitations
    • 1.4.1 Assumptions
    • 1.4.2 Limitations
  • 1.5 Market Structure

2 Research Methodology

  • 2.1 Research Process
  • 2.2 Primary Research
  • 2.3 Secondary Research

3 Market Dynamics

  • 3.1 Drivers
    • 3.1.1 Introduction
    • 3.1.2 Development of New Drugs and Therapies
    • 3.1.3 Financial Support from CFF in Research and Development of CF Drugs.
  • 3.2 Restraints
    • 3.2.1 Introduction
    • 3.2.2 High Cost of the Drugs and Treatment
  • 3.3 Opportunities
  • 3.4 Challenges
    • 3.4.1 Awareness About the Rare Disease in the Developing Countries

4 Market Factor Analysis

  • 4.1 Porter's Five Forces Model
    • 4.1.1 Bargaining Power of Suppliers
    • 4.1.2 Bargaining Power of Buyers
    • 4.1.3 Threat of New Entrants
    • 4.1.4 Threat of Substitutes
    • 4.1.5 Intensity of Rivalry

5 Cystic Fibrosis Market, By Treatment Method

  • 5.1 Introduction
  • 5.2 Medication
  • 5.3 Devices
  • 5.4 Other Treatments

6 Cystic Fibrosis Market, By Regions

  • 6.1 Introduction
  • 6.2 North America
  • 6.3 Europe
  • 6.4 Asia-Pacific
  • 6.5 Middle East & Africa

7 Company Share Analysis

8 Company Profile

  • 8.1 AbbVie
    • 8.1.1 Company Overview
    • 8.1.2 Product Overview
    • 8.1.3 Financials
    • 8.1.4 Key Developments
  • 8.2 Allergan Plc
    • 8.2.1 Company Overview
    • 8.2.2 Product Overview
    • 8.2.3 Financials
    • 8.2.4 Key Developments
  • 8.3 Chiesi Farmaceutici S.p.A.
    • 8.3.1 Company Overview
    • 8.3.2 Product/Business Segment Overview
    • 8.3.3 Financials
    • 8.3.4 Key Developments
  • 8.4 F. Hoffmann-La Roche AG
    • 8.4.1 Company Overview
    • 8.4.2 Product/Business Segment Overview
    • 8.4.3 Financials
    • 8.4.4 Key Developments
  • 8.5 Gilead Sciences
    • 8.5.1 Company Overview
    • 8.5.2 Product Overview
    • 8.5.3 Financials
    • 8.5.4 Key Developments
  • 8.6 Novartis AG
    • 8.6.1 Company Overview
    • 8.6.2 Product Overview
    • 8.6.3 Financials
    • 8.6.4 Key Developments

  • 8.7 Pharmaxis Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Product Overview
    • 8.7.3 Financials
    • 8.7.4 Key Developments
  • 8.8 PTC Therapeutics
    • 8.8.1 Company Overview
    • 8.8.2 Product Overview
    • 8.8.3 Financials
    • 8.8.4 Key Developments
  • 8.9 Vertex Pharmaceuticals Incorporated
    • 8.9.1 Company Overview
    • 8.9.2 Product/Business Segment Overview
    • 8.9.3 Financials

List of Tables

List of Tables:

  • TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 2 GLOBAL CYSTIC FIBROSIS MEDICATION MARKET, BY REGION, 2013-2027 ($MILLION)
  • TABLE 3 GLOBAL CYSTIC FIBROSIS DEVICES MARKET, BY REGION, 2013-2027 ($MILLION)
  • TABLE 4 GLOBAL CYSTIC FIBROSIS OTHER TREATMENTS MARKET, BY REGION, 2013-2027 ($MILLION)
  • TABLE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION)
  • TABLE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
  • TABLE 7 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 8 U.S. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 9 CANADA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 10 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
  • TABLE 11 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 12 GERMANY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 13 FRANCE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 14 U.K. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 15 ITALY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 16 SPAIN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 17 REST OF WESTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 18 EASTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 19 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
  • TABLE 20 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 21 AUSTRALIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 22 JAPAN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 23 CHINA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 24 INDIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 25 REPUBLIC OF KOREA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 26 REST OF ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 27 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION)
  • TABLE 28 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 29 MIDDLE EAST CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 30 AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
  • TABLE 31 CHIESI FARMACEUTICI S.P.A.: KEY DEVELOPMENTS
  • TABLE 32 VERTEX PHARMACEUTICALS INCORPORATED: KEY DEVELOPMENTS

List of Figures

List of Figures:

  • FIGURE 1 RESEARCH PROCESS OF MRFR
  • FIGURE 2 PORTER'S 5 FORCES ANALYSIS OF GLOBAL CYSTIC FIBROSIS MARKET
  • FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)
  • FIGURE 5 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 7 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 8 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 9 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
  • FIGURE 10 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 % 2022 ($MILLION)
  • FIGURE 11 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)
  • FIGURE 12 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
  • FIGURE 13 CYSTIC FINROSIS MARKET SHARE, 2016 (%)
  • FIGURE 14 ABBVIE: RECENT FINANCIAL
  • FIGURE 15 ABBVIE: BUSINESS REVENUE, 2015 (%)
  • FIGURE 16 ABBVIE: GEOGRAPHIC REVENUE, 2015 (%)
  • FIGURE 17 ALLERGAN: RECENT FINANCIAL
  • FIGURE 18 ALLERGAN: BUSINESS REVENUE, 2015 (%)
  • FIGURE 19 ALLERGAN: GEOGRAPHIC REVENUE, 2015 (%)
  • FIGURE 20 CHIESI FARMACEUTICI S.P.A.: RECENT FINANCIALS
  • FIGURE 21 F. HOFFMANN-LA ROCHE AG.: RECENT FINANCIALS
  • FIGURE 22 F. HOFFMANN-LA ROCHE AG.: BUSINESS REVENUE
  • FIGURE 23 GILEAD SCIENCES: RECENT FINANCIAL
  • FIGURE 24 NOVARTIS AG: RECENT FINANCIALS
  • FIGURE 25 NOVARTIS AG: BUSINESS REVENUE, 2015 (%)
  • FIGURE 26 NOVARTIS AG: GEOGRAPHIC REVENUE, 2015 (%)
  • FIGURE 27 PHARMAXIS LTD: RECENT FINANCIALS
  • FIGURE 28 PTC THERAPEUTICS: RECENT FINANCIALS
  • FIGURE 29 PTC THERAPEUTICS: GEOGRAPHICAL REVENUE (%)
  • FIGURE 30 PTC THERAPEUTICS: R&D EXPENSES, 2015 (%)
  • FIGURE 31 VERTEX PHARMACEUTICALS INCORPORATED: RECENT FINANCIALS
  • FIGURE 32 VERTEX PHARMACEUTICALS INCORPORATED: BUSINESS REVENUE
  • FIGURE 33 VERTEX PHARMACEUTICALS INCORPORATED: GEOGRAPHICAL REVENUE
Back to Top